The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences’ supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets to treat chronic hepatitis B virus (HBV) in paediatric patients.
Baseimmune, a biotech firm specialising in artificial intelligence (AI)-driven vaccine development, has announced the successful closure of a £9m Series A funding round.
Exicure and Bluejay Therapeutics have reached a patent licencing agreement for the development of cavrotolimod as a potential hepatitis treatment.
Novartis has acquired US-based clinical-stage biopharmaceutical company Chinook Therapeutics for up to $3.5bn upfront.
The US Food and Drug Administration (FDA) has granted clearance to Gilead Sciences’ supplemental new drug application (sNDA) of Veklury (remdesivir) for use in Covid-19 patients.
Medicines Patent Pool (MPP), a UN-supported international public health organisation, has signed seven sublicence agreements for Japanese pharmaceutical firm Shionogi & Co's Ensitrelvir fumaric acid.
Innoviva Specialty Therapeutics has received approval from the US Food and Drug Administration (FDA) for XACDURO to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
The US Food and Drug Administration (FDA) has finished a filing review of Valneva’s Biologics License Application (BLA) for single-shot chikungunya vaccine candidate VLA1553.
Daiichi Sankyo has submitted an application to the regulatory authorities in Japan seeking marketing approval of DS-5670.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has given approval to Beyfortus (nirsevimab) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.